Cardiovascular benefits from diabetes drug aren’t for all

More work needs to be done to examine the real world effects of empagliflozin, new research finds Examining data from over 60,000 patients with type 2 diabetes, researchers from the University of Surrey found that the highly-publicised cardiovascular benefits of empagliflozin cannot be applied to the majority of patients with the illness. The study, Sodium-Glucose